Cullen/Frost Bankers’s Moderna MRNA Stock Holding History

Cullen/Frost Bankers’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14	Closed	-$413	–	1504
2025 Q4	$413	Buy	+14	New	+$380	﹤0.01%	1361
2025 Q1	–	Sell	-23	Closed	-$956	–	1418
2024 Q4	$956	Hold	23	–	–	﹤0.01%	1255
2024 Q3	$1.54K	Sell	23 -8	-26%	-$734	﹤0.01%	1138
2024 Q2	$3.68K	Buy	31 +17	+121%	+$2.15K	﹤0.01%	1003
2024 Q1	$1.49K	Sell	14 -18	-56%	-$1.81K	﹤0.01%	961
2023 Q4	$3.18K	Buy	+32	New	+$2.69K	﹤0.01%	907
2023 Q3	–	Sell	-337	Closed	-$40.9K	–	1184
2023 Q2	$40.9K	Hold	337	–	–	﹤0.01%	757
2023 Q1	$51.8K	Buy	337 +333	+8,325%	+$54.9K	﹤0.01%	712
2022 Q4	$718	Sell	4 -3	-43%	-$491	﹤0.01%	1065
2022 Q3	$1K	Sell	7 -193	-97%	-$29.3K	﹤0.01%	1105
2022 Q2	$29K	Hold	200	–	–	﹤0.01%	788
2022 Q1	$34K	Hold	200	–	–	﹤0.01%	804
2021 Q4	$51K	Hold	200	–	–	﹤0.01%	750
2021 Q3	$77K	Buy	+200	New	+$73.8K	﹤0.01%	666

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cullen/Frost Bankers's MRNA Position: Q1 2026 in Review

Cullen/Frost Bankers sold out of Moderna (MRNA) in Q1 2026, closing a stake of 14 shares — an estimated $413 sold.

Cullen/Frost Bankers first reported a position in MRNA in Q3 2021 and held it in 14 quarters. The position peaked at $77K in Q3 2021. 726 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

Cullen/Frost Bankers reported no remaining Moderna position as of Q1 2026 after selling out during the quarter.
Cullen/Frost Bankers sold 14 Moderna shares in Q1 2026, an estimated $413.
Cullen/Frost Bankers first reported a position in Moderna in Q3 2021 and held it in 14 quarters.
Cullen/Frost Bankers's Moderna position peaked at $77K in Q3 2021.
726 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Cullen/Frost Bankers's 13F filing for Q1 2026, filed 5 May 2026.